BioMarin Pharmaceutical (0HNC) Share Forecast & Price Target
0HNC Analyst Ratings
0HNC Stock 12 Month Forecast
Average Price Target
$91.73▲(57.63% Upside)Detailed List of Analyst Forecasts​
| Analyst Profile | Expert Firm | Price Target | Position | Upside / Downside | Action | Date | Follow | Article |
|---|---|---|---|---|---|---|---|---|
| Whitney Ijem | Canaccord Genuity | $114 | buy | 95.91%Upside | Reiterated | 10/29/26 | ||
| Jack Allen | Robert W. Baird | $65 | hold | 11.70%Upside | Reiterated | 10/27/26 | ||
| Allison Bratzel | Piper Sandler | $90 | buy | 54.67%Upside | Reiterated | 10/21/26 | ||
| Sean Laaman | Morgan Stanley | $124→$122 | buy | 109.66%Upside | Assigned | 10/21/26 | ||
| Phil Nadeau | TD Cowen | $120 | buy | 106.22%Upside | Reiterated | 10/21/26 | ||
| Mohit Bansal | Wells Fargo | $80 | buy | 37.48%Upside | Assigned | 10/20/26 | ||
| Jessica Fye | J.P. Morgan | $86→$87 | buy | 49.51%Upside | Assigned | 10/20/26 | ||
| Olivia Brayer | Cantor Fitzgerald | $86 | buy | 47.79%Upside | Reiterated | 10/19/26 | ||
| Joon Lee | UBS | $114→$88 | buy | 51.23%Upside | Assigned | 10/15/26 | ||
| Eliana Merle | Barclays | $111→$114 | buy | 95.91%Upside | Reiterated | 10/13/26 | ||
| Jason Gerberry | Bank of America Securities | $86 | buy | 47.79%Upside | Reiterated | 10/09/26 | ||
| Luca Issi | RBC Capital | $62 | hold | 6.55%Upside | Reiterated | 10/08/26 | ||
| David Lebowitz | BMO Capital | $97 | buy | 66.70%Upside | Reiterated | 10/06/26 | ||
| Debjit Chattopadhyay | Guggenheim | $86 | buy | 47.79%Upside | Reiterated | 09/17/26 | ||
| Eric Joseph | Citi | ― | buy | ― | Reiterated | 09/14/26 |
| Analyst Profile | Date | Price Target | Position | Upside / Downside | Action | Follow | Article | Expert Firm |
|---|---|---|---|---|---|---|---|---|
| Whitney Ijem | 10/29/26 | $114 | buy | 95.91%Upside | Reiterated | Canaccord Genuity | ||
| Jack Allen | 10/27/26 | $65 | hold | 11.70%Upside | Reiterated | Robert W. Baird | ||
| Allison Bratzel | 10/21/26 | $90 | buy | 54.67%Upside | Reiterated | Piper Sandler | ||
| Sean Laaman | 10/21/26 | $124→$122 | buy | 109.66%Upside | Assigned | Morgan Stanley | ||
| Phil Nadeau | 10/21/26 | $120 | buy | 106.22%Upside | Reiterated | TD Cowen | ||
| Mohit Bansal | 10/20/26 | $80 | buy | 37.48%Upside | Assigned | Wells Fargo | ||
| Jessica Fye | 10/20/26 | $86→$87 | buy | 49.51%Upside | Assigned | J.P. Morgan | ||
| Olivia Brayer | 10/19/26 | $86 | buy | 47.79%Upside | Reiterated | Cantor Fitzgerald | ||
| Joon Lee | 10/15/26 | $114→$88 | buy | 51.23%Upside | Assigned | UBS | ||
| Eliana Merle | 10/13/26 | $111→$114 | buy | 95.91%Upside | Reiterated | Barclays | ||
| Jason Gerberry | 10/09/26 | $86 | buy | 47.79%Upside | Reiterated | Bank of America Securities | ||
| Luca Issi | 10/08/26 | $62 | hold | 6.55%Upside | Reiterated | RBC Capital | ||
| David Lebowitz | 10/06/26 | $97 | buy | 66.70%Upside | Reiterated | BMO Capital | ||
| Debjit Chattopadhyay | 09/17/26 | $86 | buy | 47.79%Upside | Reiterated | Guggenheim | ||
| Eric Joseph | 09/14/26 | ― | buy | ― | Reiterated | Citi |
Best Analysts Covering BioMarin Pharmaceutical
Copying Christopher Raymond's trades and holding each position for 3 Months would result in 41.67% of your transactions generating a profit, with an average return of -0.38% per trade.
Copying Cory Kasimov's trades and holding each position for 1 Year would result in 46.51% of your transactions generating a profit, with an average return of -4.18% per trade.
Copying Cory Kasimov's trades and holding each position for 2 Years would result in 41.86% of your transactions generating a profit, with an average return of -2.07% per trade.
0HNC Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 26 | 25 | 16 | 17 | 26 |
| Buy | 6 | 7 | 10 | 17 | 17 |
| Hold | 10 | 13 | 14 | 15 | 13 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 42 | 45 | 40 | 49 | 56 |
In the current month, 0HNC has received 43 Buy Ratings, 13 Hold Ratings, and 0 Sell Ratings. 0HNC average Analyst price target in the past 3 months is 91.73.
0HNC Financial Forecast
0HNC Earnings Forecast
Next quarter’s earnings estimate for 0HNC is -$0.08 with a range of -$0.48 to $0.24. The previous quarter’s EPS was $1.20. 0HNC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0HNC has Performed in-line its overall industry.
0HNC Sales Forecast
Next quarter’s sales forecast for 0HNC is $1.02B with a range of $999.00M to $1.05B. The previous quarter’s sales results were $996.38M. 0HNC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0HNC has Performed in-line its overall industry.